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P.029) and CHF (2.1% vs 0.6%; P.005). In multivar-
iate analysis, dextran was associated with a higher risk of
perioperative MI (OR, 5.2; CI,1.9-14.4; P.002) and
CHF (OR, 5.9; CI,1.9-18.5; P0.002).
Conclusions: Dextran use was not associated with
perioperative stroke but was associated with higher rates of
MI and CHF. Taken together, our findings suggest limited
clinical utility for dextran.
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Objectives: CMS requires high risk criteria for CAS
reimbursement. The impact of these criteria on outcomes
remains uncertain, potentially biasing comparative effec-
tiveness analysis. We evaluate this using data from the SVS
Vascular Registry™.
Methods: We analyzed 10,107 patients undergoing
CEA (6370) and CAS (3737). Patients were stratified by
CMS high risk (HR) criteria. The primary endpoint was
composite death, stroke and MI (MACE) at 30 days.
Results: CAS patients were more likely to have preop-
erative stroke (26 v 21%) or TIA (23 v 19%) than CEA.
While age 80years was similar, CAS had higher preva-
lence of all other HR criteria. For CEA, HR patients had
higher MACE than normal risk: SX (7.3 v 4.6%, P.01)
and ASX (5 vs 2.2%; P.0001). For CAS there was no
difference: SX (9.1 vs 6.2%; P.24) or ASX (5.4 vs 4.2%;
P.61) All CAS patients had MACE rates similar to HR
CEA. After risk adjustment, CAS had higher rates than
CEA for MACE (OR, 1.2; 95%CI, 1.0-1.5), death (1.5,
1.0-2.2) and stroke (1.3, 1.0-1.7), while there was no
difference in MI (OR, 0.8, 0.6-1.3). Multivariate analyses
for predictors of MACE are reported in the Table. Radia-
tion and restenosis were protective for MACE from CAS.
Conclusions: CEA is safer in the majority of patients
with carotid disease. Normal risk CAS may be confined to
restenosis and radiation.
Table. Multivariate logistic models for 30-day MACE
CEA - Risk factors
Odds
ratio 95% CI P value
Symptomatic 1.831 1.426-2.351 .0001
Age 80y 1.370 1.024-1.833 .0341
CHF class III/IV 1.707 1.027-2.839 .0392
LVEF 30% 3.529 1.620-7.690 .0015
Angina 3.920 1.545-9.942 .0040
Contralateral occlusion 3.164 2.112-4.738 .0001
High anatomic lesion 2.723 1.321-5.616 .0067
CAS - Risk factors
Odds
ratio 95% CI P value
Symptomatic 1.674 1.292-2.170 .0001
Recent MI 3.433 1.674-7.043 .0008
Restenosis 0.591 0.430-0.813 .0012
Prior radiation to neck 0.418 0.225-0.776 .0057
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Table.
Characteristics
Crude sample Group matched sample Propensity matched sample
Dextran, %
(n443)
No Dextran, %
(n6397) P value
Dextran, %
(n333)
No Dextran, %
(n1523) P value
Dextran, %
(n334)
No Dextran, %
(n1670) P value
General
Anesthesia
74.3 88.9 .001 74.5 79.3 0.06 74.3 73.5 .84
Eversion 19.2 10.0 .001 19.2 24.7 0.03 19.2 19.2 .99
Shunt 18.9 48.6 .001 18.9 20.1 0.65 18.9 23.2 .10
Outcomes
Stroke or death 1.2 1.0 .58 1.2 0.6 0.27 1.2 0.7 .32
MI 2.4 1.0 .03 2.4 0.6 0.005 2.4 0.5 .003
CHF 2.1 0.6 .005 2.1 0.5 0.006 2.1 0.2 .001
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